Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results Exceeding Estimates
Vanda Pharmaceuticals (VNDA) reported third-quarter financial results that surpassed analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.37, which outperformed estimates by $0.31, while quarterly revenue reached $69.82 million, representing a 24% increase year-over-year and beating projections by $0.7 million. Despite the top-line growth, the company's liquidity position saw a reduction during the period. As of September 30, 2026, Vanda reported cash, cash equivalents, and marketable securities totaling $140.5 million, marking a decrease of $29.5 million compared to previous holdings.
Topics: cash flow earnings beat GAAP EPS revenue growth